| Filed On | Filing |
|---|---|
| 07 Nov 2024 |
8-K/A: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
On November 1, 2024, Estrella Immunopharma, Inc. (the “Company”) entered into a Consulting Agreement (the “Consulting Agreement”) with Cofame Investment Management Co. Ltd. (“Consultant” or “Cofame”), a company owned and controlled by Ms... |
| 14 Nov 2023 |
8-K/A: Amendments to Articles/Bylaws; Change in Fiscal Year
Effective as of the closing date of the Business Combination on September 29, 2023, the Company’s fiscal year end changed from December 31 to June 30. This change aligns the Company’s fiscal year and financial reporting periods with that... |
Loading...
